186 related articles for article (PubMed ID: 12422138)
1. Esmolol in acute ischemic syndromes.
Mitchell RG; Stoddard MF; Ben-Yehuda O; Aggarwal KB; Allenby KS; Trillo RA; Loyd R; Chang CT; Labovitz AJ
Am Heart J; 2002 Nov; 144(5):E9. PubMed ID: 12422138
[TBL] [Abstract][Full Text] [Related]
2. Safety of esmolol in patients with acute myocardial infarction treated with thrombolytic therapy who had relative contraindications to beta-blocker therapy.
Mooss AN; Hilleman DE; Mohiuddin SM; Hunter CB
Ann Pharmacother; 1994 Jun; 28(6):701-3. PubMed ID: 7919552
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience with esmolol, a short-acting beta-adrenergic blocker in cardiac arrhythmias and myocardial ischemia.
Sung RJ; Blanski L; Kirshenbaum J; MacCosbe P; Turlapaty P; Laddu AR
J Clin Pharmacol; 1986 Mar; 26(S1):A15-A26. PubMed ID: 2870082
[TBL] [Abstract][Full Text] [Related]
4. Nonthrombolytic intervention in acute myocardial infarction.
Kirshenbaum JM
Am J Cardiol; 1989 Jul; 64(4):25B-28B. PubMed ID: 2568748
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of esmolol for unstable angina pectoris.
Wallis DE; Pope C; Littman WJ; Scanlon PJ
Am J Cardiol; 1988 Nov; 62(16):1033-7. PubMed ID: 2903659
[TBL] [Abstract][Full Text] [Related]
6. Usefulness of esmolol in unstable angina pectoris. European Esmolol Study Group.
Hohnloser SH; Meinertz T; Klingenheben T; Sydow B; Just H
Am J Cardiol; 1991 Jun; 67(16):1319-23. PubMed ID: 1675036
[TBL] [Abstract][Full Text] [Related]
7. Clinical rationale for the use of an ultra-short acting beta-blocker: esmolol.
Barbier GH; Shettigar UR; Appunn DO
Int J Clin Pharmacol Ther; 1995 Apr; 33(4):212-8. PubMed ID: 7620691
[TBL] [Abstract][Full Text] [Related]
8. Intravenous esmolol is well tolerated in elderly patients with heart failure in the early phase of non-ST elevation myocardial infarction.
Koutouzis M; Nikolidakis S; Grigoriadis A; Koutsogeorgis D; Kyriakides ZS
Drugs Aging; 2006; 23(8):673-80. PubMed ID: 16964989
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the potassium channel blocker tedisamil with the beta-adrenoceptor blocker esmolol and the calcium antagonist gallopamil in patients with coronary artery disease.
Mitrovic V; Oehm E; Thormann J; Pitschner H; Haberbosch W
Clin Cardiol; 1998 Jul; 21(7):492-502. PubMed ID: 9669058
[TBL] [Abstract][Full Text] [Related]
10. Randomized Control of Sympathetic Drive With Continuous Intravenous Esmolol in Patients With Acute ST-Segment Elevation Myocardial Infarction: The BEtA-Blocker Therapy in Acute Myocardial Infarction (BEAT-AMI) Trial.
Er F; Dahlem KM; Nia AM; Erdmann E; Waltenberger J; Hellmich M; Kuhr K; Le MT; Herrfurth T; Taghiyev Z; Biesenbach E; Yüksel D; Eran-Ergöknil A; Vanezi M; Caglayan E; Gassanov N
JACC Cardiovasc Interv; 2016 Feb; 9(3):231-240. PubMed ID: 26847114
[TBL] [Abstract][Full Text] [Related]
11. Acute hemodynamic effects of beta-blockers in patients with severe congestive heart failure: comparison of celiprolol and esmolol.
Felix SB; Stangl V; Kieback A; Doerffel W; Staudt A; Wernecke KD; Baumann G; Stangl K
J Cardiovasc Pharmacol; 2001 Nov; 38(5):666-71. PubMed ID: 11602813
[TBL] [Abstract][Full Text] [Related]
12. Acute effects of nicardipine and esmolol on the cardiac cycle, intracardiac hemodynamic and endothelial shear stress in patients with unstable angina pectoris and moderate coronary stenosis: results from single center, randomized study.
Chen SL; Hu ZY; Zhang JJ; Ye F; Kan J; Xu T; Liu ZZ; Zhang YJ; Zhang JX; Chen M
Cardiovasc Ther; 2012 Jun; 30(3):162-71. PubMed ID: 22099625
[TBL] [Abstract][Full Text] [Related]
13. Ultra short-acting intravenous beta-adrenergic blockade as add-on therapy in acute unstable angina.
Barth C; Ojile M; Pearson AC; Labovitz AJ
Am Heart J; 1991 Mar; 121(3 Pt 1):782-8. PubMed ID: 1672051
[TBL] [Abstract][Full Text] [Related]
14. Esmolol: a titratable short-acting intravenous beta blocker for acute critical care settings.
Turlapaty P; Laddu A; Murthy VS; Singh B; Lee R
Am Heart J; 1987 Oct; 114(4 Pt 1):866-85. PubMed ID: 2889341
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of intravenous esmolol for cardiac protection in non-cardiac surgery. A systematic review and meta-analysis.
Ollila A; Vikatmaa L; Sund R; Pettilä V; Wilkman E
Ann Med; 2019 Feb; 51(1):17-27. PubMed ID: 30346213
[TBL] [Abstract][Full Text] [Related]
16. Use of an ultrashort-acting beta-receptor blocker (esmolol) in patients with acute myocardial ischemia and relative contraindications to beta-blockade therapy.
Kirshenbaum JM; Kloner RF; McGowan N; Antman EM
J Am Coll Cardiol; 1988 Sep; 12(3):773-80. PubMed ID: 2900259
[TBL] [Abstract][Full Text] [Related]
17. Effect of esmolol on oxidant status and antioxidant activity in acute myocardial infarction.
Daga MK; Chaudhary M; Sharma B; Bhattacharjee J; Ghambhir DS; Arora N; Sudha R
J Assoc Physicians India; 2003 Jul; 51():677-80. PubMed ID: 14621036
[TBL] [Abstract][Full Text] [Related]
18. Randomized study of early intravenous esmolol versus oral beta-blockers in preventing post-CABG atrial fibrillation in high risk patients identified by signal-averaged ECG: results of a pilot study.
Balcetyte-Harris N; Tamis JE; Homel P; Menchavez E; Steinberg JS
Ann Noninvasive Electrocardiol; 2002 Apr; 7(2):86-91. PubMed ID: 12049678
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the efficacy and safety of esmolol, a short-acting beta blocker, with placebo in the treatment of supraventricular tachyarrhythmias. The Esmolol vs Placebo Multicenter Study Group.
Anderson S; Blanski L; Byrd RC; Das G; Engler R; Laddu A; Lee R; Rajfer S; Schroeder J; Steck JD
Am Heart J; 1986 Jan; 111(1):42-8. PubMed ID: 2868645
[TBL] [Abstract][Full Text] [Related]
20. Managing critically ill patients with esmolol. An ultra short-acting beta-adrenergic blocker.
Gray RJ
Chest; 1988 Feb; 93(2):398-403. PubMed ID: 2892647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]